Table 2.
Quality assessment of included studies
| Agency for Healthcare Research and Quality | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study | Item | Score | ||||||||||
| Define source of information (survey or review) | List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications |
Indicate time period used to identify patients |
Indicate whether subjects were consecutive if not population- based |
Indicate if evaluators of subjective components of study were masked to, Other aspects of the status of the participants | Describe any assessments undertaken for quality assurance purposes | Explain any patient exclusions from analysis | Describe how confounding variables were assessed or controlled for | If applicable, explain how missing data were handled in the analysis | Summarise patient response rate and completeness of data collection | Clarify what follow-up, if any, was expected and the percentage of patients for whom incomplete data or follow-up was obtained | ||
| Yi-Liang (2015) [20] | Y | Y | Y | U | U | Y | N | Y | N | Y | N | 6 |
| Ito (2018) [21] | Y | Y | Y | U | N | Y | N | N | U | Y | N | 5 |
| Brumagne (2004) [22] | Y | N | N | N | U | Y | N | Y | U | Y | N | 4 |
| Ito (2017) [23] | Y | Y | Y | U | N | Y | N | Y | U | Y | N | 6 |
| Lee (2016) [24] | Y | Y | Y | U | N | Y | N | Y | N | Y | N | 6 |
| Iversen (2009) [25] | Y | Y | Y | U | U | Y | N | Y | N | Y | N | 6 |
| Kendall (2018) [26] | Y | Y | Y | U | N | Y | N | Y | N | Y | N | 6 |
| Sung (2017) [27] | Y | Y | Y | Y | N | Y | N | Y | N | Y | N | 7 |
|
Lihavainen (2010) [28] |
Y | Y | N | Y | N | N | Y | N | Y | Y | N | 6 |
|
Champagne (2012) [29] |
Y | Y | N | Y | N | Y | N | N | Y | Y | N | 6 |
| Hicks (2018) [30] | Y | Y | Y | U | N | Y | N | N | N | Y | N | 5 |
| Silva (2016) [31] | Y | Y | Y | Y | N | Y | N | N | N | Y | N | 6 |
| Kato (2019) [32] | Y | Y | N | Y | N | Y | N | U | N | Y | N | 5 |
N NO, Y YES, U UNCLEAR